Transaction · 0002050172-26-000003

Bernstein Harold

Bernstein Harold, PRES, R, D, CMO, reported an open-market or private sale at Maze Therapeutics, Inc. involving 4432.000000 shares for an estimated $179187.53. Reported holdings after the transaction were 0.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SPRES, R, D, CMO
MAZEMaze Therapeutics, Inc.
Filing timeJan 06
Trade dateJan 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
…
Pre-filing
…
Returns since
…

MAZE price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
MAZE since 2026-01-06Filed 242 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002050172-26-000003
Common Stock
Transaction date
Jan 02, 2026
Filed Jan 06, 2026, 09:31 PM · 4d delay
Shares
4.43k sh
$4.04k per share
Estimated value
-$17.9M
Computed from shares × price
Holdings after
0 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership 10b5-1 Detected
-4score
Filing-only score

-4

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, R&D & CMO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.

  2. F2

    The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.965 per share, inclusive. The reporting person undertak…

  3. F3

    The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person'…

Original filing · 0002050172-26-000003
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

MAZE